CAR T-Cell Therapy Shows Promise for Autoimmune Diseases | Healio

A new wave of optimism is building in the treatment of autoimmune diseases, fueled by promising results from clinical trials utilizing CAR T-cell therapy. Initially developed to combat blood cancers, this innovative approach is now showing potential to “reset” the immune system in conditions like systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, ulcerative colitis, rheumatoid arthritis, and lupus.

CAR T-cell therapy, first approved by the Food and Drug Administration (FDA) in 2017 for certain B-cell lymphomas, involves extracting a patient’s own T cells and genetically engineering them to express a chimeric antigen receptor (CAR). This CAR allows the T cells to target specific cells contributing to the disease process. Once reintroduced into the body, these “supercharged” T cells work to attack the disease, offering a potential solution for patients who haven’t responded to traditional treatments.

The University of Chicago Medicine is currently conducting Phase 2 clinical trials investigating the efficacy of CAR T-cell therapy in treating systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis (also known as systemic scleroderma). This makes UChicago Medicine one of nine sites involved in these groundbreaking trials.

Recent presentations at medical conferences, including EULAR 2025 and ACR Convergence 2025, have highlighted the significant potential of this therapy. Data presented at EULAR 2025 showed that patients with systemic lupus erythematosus experienced potent B-cell depletion and subsequent recovery, alongside improvements in disease activity. Researchers are observing “deep B-cell depletion, leading to marked clinical effects” in patients with severe, refractory SLE.

Dr. Albert C. Yeh, a physician and research associate at Fred Hutch Cancer Center and acting assistant professor at the University of Washington School of Medicine, noted the intriguing observation that there are actually more cases of autoimmune diseases than cancer cases currently treatable with CAR T-cell therapy. This suggests a potentially broader application for the therapy than initially anticipated.

Currently, the standard treatment for autoimmune diseases often relies on glucocorticoids, such as prednisone, used in combination with other medications. While these medications can manage symptoms, they often require lifelong treatment and carry a significant risk of side effects. Symptoms frequently return upon discontinuation of these medications. CAR T-cell therapy may offer a more durable solution, potentially providing long-term remission for patients who have not found relief with conventional therapies.

The success of CAR T-cell therapy hinges on its ability to induce a targeted immune response. In autoimmune diseases, the immune system mistakenly attacks the body’s own tissues. CAR T-cell therapy aims to recalibrate this response, specifically targeting the immune cells responsible for the autoimmune attack. The therapy has demonstrated the ability to achieve a significant “immune reset,” as observed in studies of systemic lupus erythematosus.

Beyond lupus and scleroderma, research is expanding to include ulcerative colitis and rheumatoid arthritis. A case study published in June 2025 detailed positive outcomes in patients with ulcerative colitis, a condition affecting the colon and causing stomach pain, ulcers, and bloody diarrhea. This suggests the therapy’s potential applicability across a wide spectrum of autoimmune conditions.

While the results are encouraging, it’s important to note that CAR T-cell therapy is not without its complexities. Researchers are actively monitoring for potential autoimmune impacts following treatment, recognizing the need for careful evaluation and management of any adverse effects. Further research is crucial to fully understand the long-term effects and optimize the therapy for different autoimmune diseases.

The field of cellular therapy is rapidly evolving, with ongoing investigations into gene therapy and the application of artificial intelligence to enhance treatment strategies. As Dr. Yeh emphasized, recent meetings have showcased a “lot of variety” in these advancements, signaling a dynamic and promising future for the treatment of autoimmune diseases and beyond.